CN103755719A - Physalin B crystal and extraction and preparation methods as well as application of physalin B crystal in preparing anti-inflammatory medicines - Google Patents
Physalin B crystal and extraction and preparation methods as well as application of physalin B crystal in preparing anti-inflammatory medicines Download PDFInfo
- Publication number
- CN103755719A CN103755719A CN201310754683.5A CN201310754683A CN103755719A CN 103755719 A CN103755719 A CN 103755719A CN 201310754683 A CN201310754683 A CN 201310754683A CN 103755719 A CN103755719 A CN 103755719A
- Authority
- CN
- China
- Prior art keywords
- physalin
- crystal
- ethyl acetate
- solvent
- sherwood oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a physalin B crystal which belongs to a monoclinic system, wherein the space group is P2(1); the lattice parameters (i)a(/i) is equal to 12.4996 (2), (i)b(/i) is equal to 14.35620(10), (i)c(/i) is equal to 14.75190(10) and (i)beta(/i) is equal to 99.8740(10) degrees; the volume of the crystal cell is 2607.97(5)3; the crystalline density is 1.382mg/m<3>; (i)Z(/i) is equal to 4; F(000) is equal to 1152; the final departure factors (i)R1(/i) is equal to 0.0407, and (i)wR2(/i) is equal to 0.1056. The invention further discloses an extraction method of the crystal. The extraction method comprises the following steps: 1) extracting a physalis plant material to remove a solvent to obtain an extract; 2) repeatedly dissolving soluble parts of the extract by petroleum ether, standing and filtering; 3) repeatedly dissolving the extract treated by petroleum ether by ethyl acetate, standing, filtering, combining the filtrate and removing the solvent to obtain a solid; and 4) dissolving the solid, mixing a sample by silica gel, passing through a column by a dry method, carrying out gradient elution, collecting an eluant, repeatedly carrying out column chromatography, and finally, removing the solvent from the eluant. The invention further discloses an application of the physalin B crystal in preparing anti-inflammatory medicines. The crystal obtained by the invention has higher anti-inflammatory activity.
Description
Technical field
The present invention relates to Physalin B crystal and extract preparation method and the application of Physalin B crystal in preparing anti-inflammation drugs.
Background technology
Inflammatory reaction is that body is to one of important defense mechanism of physics, chemistry, immunity or histocyte that biotic factor causes damage, also be the basic pathology process that development occurs various diseases, the pathogenic process of numerous disease has the participation of inflammatory mediator, some diseases associated with inflammation (as rheumatoid arthritis, rheumatic fever, osteoarthritis), asthma, chronic obstructive lung illness, wound, burn, endotoxin shock, alzheimer's disease, even heart failure etc. has the participation of inflammatory mediator.
Anti-inflammatory drug is divided into steroidal (adrenocortical hormones) and the large class of NSAID (non-steroidal anti-inflammatory drug) (NSAIDs) two, and adrenocortical hormone is the general name of the secreted hormone of adrenal cortex, belongs to steroid compound.Can be divided into 1. mineralocorticoid.2. glucocorticosteroid etc.Glucocorticosteroid effect is extensively and complicated, and its main pharmacological comprises anti-inflammatory, immunosuppression, antishock etc.It is severe infections or inflammation that glucocorticoids medicine one of is mainly applied, as toxic dysentery, fulminant type epidemic meningitis, toxic pneumonitis etc.But with after can reduce the defence capability of body and make to infect diffusion; Glucocorticoid medicine untoward reaction is many, comprising: 1. long-term extensive application causes substance metabolism and water and salt metabolic disturbance.Easily cause hemo-hyperadrenocorticism syndrome; 2. bring out or increase the weight of and infect; 3. digestive complications: can bring out or aggravate Stomach duodenum ulcer, even cause digestive tract hemorrhage or perforation.4. prolonged application can cause hypertension and atherosclerosis; 5. cause that osteoporosis, amyotrophy, wound healing are slow.6. this class medicine of life-time service can produce dependency.
One of medicine that NSAID (non-steroidal anti-inflammatory drug) is more conventional.Its structure and mechanism of action are all different from Aeroseb-Dex, but have the effects such as antipyretic, analgesia, anti-inflammatory, so be referred to as NSAID (non-steroidal anti-inflammatory drug).NSAIDs is widely used in the diseases associated with inflammation for the treatment of osteoarthritis, rheumatoid arthritis and panimmunity dysfunction clinically, and the alleviation of various pain symptoms, is a most popular class medicine in worldwide, is widely used, and market is huge.The U.S. has 6,000 ten thousand NSAIDs prescriptions every year; Domestic 7.55% Prescriptions for Out-patients is containing NSAIDs.NSAIDs previously be take acetylsalicylic acid as representative.In recent decades, the NSAIDs of different chemical structures and formulation emerges in multitude, and NSAIDs is divided into following a few class by chemical structure: (1) formic acid class also claims salicylic acid, represents that medicine has acetylsalicylic acid, diflunisal.(2) acetic acid class, represents that medicine has diclofenac, indomethacin (INDOMETHACIN), sulindac etc.(3) phenoxy propionic acid, represents that medicine has Ibuprofen BP/EP, Ketoprofen, fenbufen, Naproxen Base etc.(4) former times health class, represent that medicine has piroxicam, meloxicam, tenoxicam etc.(5) COX
2specific inhibitor former times dry goods, represents that medicine has celecoxib (celecoxib), rofecoxib.(6) pyrazolone, represents that medicine has Sulpyrine, pyramidon, Phenylbutazone etc.(7) other classes, as nimesulide etc.
NSAIDs is because 1. prostaglandin(PG) (PG) is synthetic suppressed, Oligemia; 2. medicine coup injury; 3. platelet aggregation changing function; 4. anaphylaxis; 5. many reasons such as relevant with the genetic polymorphism of drug metabolism enzyme, producing some row untoward reactions mainly contains: gi tract infringements shows as Upper abdominal pain, feels sick, maldigestion, esophagitis and colitis, and the most serious is, and gastroduodenal is rotten to the corn, ulcer and life-threatening gastric-intestinal perforation and hemorrhage; Hepatic injury, nearly all NSAIDs all has hepatic injury (being elevated to serious hepatic necrosis from slight liver enzyme).The heavy dose of life-time service of paracetamol can cause serious liver toxicity, especially the most common with hepatic necrosis; Injury of the kidney shows as acute renal insufficiency, asks matter nephritis, anodyne nephritis, necrosis of renal papillae, the storage of water sodium stay, hyperkalemia etc.; The danger that blood system and cardiovascular systems show as hemocytopenia, coagulation disorders, myocardial infarction, cardiac sudden death and apoplexy increases; Central nervous system shows as that headache, dizziness, tinnitus, deafness, eyesight change, drowsiness, insomnia, paresthesia, numbness and aseptic meningitis etc.; Anaphylaxis shows as various fash, itch, asthma etc.
At present, owing to not being also the untoward reaction that completely clear, long-term pharmacological agent brings to the pathogenesis of inflammation, also to patient, bring misery.Therefore, in following research, continue to understand the key link in inflammation development process in depth, make full use of the progress of each related discipline, from pathogenetic pathophysiological basis, find new anti-inflammatory drug action target spot tool is of great significance.
Physalin (Physalins) compounds is naturally occurring driffractive ring steroidal, basic structure is 13, 14-driffractive ring-16, 24-encircles ergosterol, it is the highest compounds of functional group's degree of oxidation in liquor-saturated eggplant lactone compound, liquor-saturated eggplant lactone (withanolides) is that a class is based on ergostane skeleton, the delta-lactone being formed by oxygen cyclization by C-22 and C-26, physalin (Physalins) compounds is considered to the highest compounds of functional group's degree of oxidation in liquor-saturated eggplant lactone compound, up to the present the physalin of bibliographical information is total to approximately more than 20 this compounds.
In physalin monomeric compound, there is at present the research of the anti-inflammatory action of Physalin B, E, F, it is reported that its effect is obviously to stop that intestinal ischemia reperfusion injury intestines and pulmonary vascular permeability increase, neutrophilic granulocyte is assembled, stop intestinal bleeding simultaneously, significantly reduce TNF-
αconcentration in serum, intestines, lung, the concentration that gives in advance the IL-10 that physalin makes to pour into animal again increases, and may be the steroid derivative of the another kind of new type natural for the treatment of of inflammatory diseases.
Summary of the invention
The object of the present invention is to provide Physalin B crystal and extract preparation method and the application of Physalin B crystal in preparing anti-inflammation drugs.
The technical solution used in the present invention is:
Physalin B crystal, this crystal belongs to oblique system, and spacer is P2 (1), unit cell parameters
a=12.4996 (2),
b=14.35620 (10),
c=14.75190 (10),
c=99.8740 (10) °, unit cell volume: 2607.97 (5)
3, crystalline density: 1.382 mg/m3, Z=4,
f(000)=1152, final discrepancy factor
r 1 =0.0407,
wR 2 =0.1056.
The extracting method of Physalin B crystal, comprises the following steps:
1) pulverizes the stem of Ku Zhi, leaf, fruit, and soaked in solvent extracts, and obtains soak solution, removes solvent and moisture in soak solution, obtains medicinal extract;
2) pulverize medicinal extract, with petroleum ether solvent, fully dissolve the soluble part in medicinal extract, sufficient standing, filters; Redissolve, sufficient standing, filters this process for several times, until be suitable in medicinal extract all being gone out by Petroleum ether extraction by the part of petroleum ether dissolution;
3) medicinal extract of upper step being processed through sherwood oil is dried, more fully dissolves the soluble part in medicinal extract by ethyl acetate, and sufficient standing filters; Redissolve, sufficient standing, filters this process for several times, until in medicinal extract, be suitable for all by ethyl acetate, being extracted by the part of acetic acid ethyl dissolution, merging filtrate, then remove the ethyl acetate in filtrate, obtain solid substance;
4) solid substance upper step being obtained obtains the solution that contains solid substance with acetic acid ethyl dissolution, in the solution that contains solid substance, add column chromatography silica gel to mix sample again, after ethyl acetate is evaporated completely, silicagel column in dry method, by sherwood oil ethyl acetate, mix gradient solvent and carry out gradient elution, TLC detects wash-out process, collect sherwood oil, the volume ratio of ethyl acetate is the elutriant of 5:1, remove the solvent in this elutriant, obtain solids, and repeatedly with sherwood oil ethyl acetate, mix gradient solvent and carry out gradient elution, finally obtain sherwood oil, the volume ratio of ethyl acetate is the elutriant of 5:1, except desolventizing can obtain Physalin B crystal,
Wherein, carry out in the sherwood oil ethyl acetate mixed solvent of gradient elution, the volume ratio of sherwood oil, ethyl acetate is respectively: 100:0; 100:1; 80:1; 50:1; 25:1; 10:1; 5:1; 3:1; 2:1; 1:1.
In step 1), solvent is the ethanol of 85-90vol%, and soaking the multiplicity of extracting is 3 times, and each soak time is 7-10 days, described method of removing solvent in soak solution and moisture is for utilizing Rotary Evaporators decompression recycling ethanol, then moisture is removed in evaporation.
Step 2), in, in each dissolution process, the consumption of sherwood oil was not for having medicinal extract.
In step 3), in each dissolution process, the consumption of ethyl acetate was not for having medicinal extract.
In step 4), the quality of solid substance and ethyl acetate volume ratio are 1g:4-5ml.
The application of described Physalin B crystal in preparing anti-inflammation drugs.
The invention has the beneficial effects as follows: the present invention extracts and prepared Physalin B crystal, has carried out the mensuration of X-single crystal diffraction, obtains its crystalline structure, the Physalin B crystal of the preparation of extracting has higher anti-inflammatory activity.
Accompanying drawing explanation
Fig. 1 is molecular structure and the atom mark of Physalin B crystal.
Embodiment
Physalin B crystal, this crystal belongs to oblique system, and spacer is P2 (1), unit cell parameters
a=12.4996 (2),
b=14.35620 (10),
c=14.75190 (10),
c=99.8740 (10) °, unit cell volume: 2607.97 (5)
3, crystalline density: 1.382 mg/m3, Z=4,
f(000)=1152, final discrepancy factor
r 1 =0.0407,
wR 2 =0.1056.
The extracting method of Physalin B crystal, comprises the following steps:
1) pulverizes the stem of Ku Zhi, leaf, fruit, and soaked in solvent extracts, and obtains soak solution, removes solvent and moisture in soak solution, obtains medicinal extract;
2) pulverize medicinal extract, with petroleum ether solvent, fully dissolve the soluble part in medicinal extract, sufficient standing, filters; Redissolve, sufficient standing, filters this process for several times, until be suitable in medicinal extract all being gone out by Petroleum ether extraction by the part of petroleum ether dissolution;
3) medicinal extract of upper step being processed through sherwood oil is dried, more fully dissolves the soluble part in medicinal extract by ethyl acetate, and sufficient standing filters; Redissolve, sufficient standing, filters this process for several times, until in medicinal extract, be suitable for all by ethyl acetate, being extracted by the part of acetic acid ethyl dissolution, merging filtrate, then remove the ethyl acetate in filtrate, obtain solid substance;
4) solid substance upper step being obtained obtains the solution that contains solid substance with acetic acid ethyl dissolution, in the solution that contains solid substance, add column chromatography silica gel to mix sample again, after ethyl acetate is evaporated completely, silicagel column in dry method, by sherwood oil ethyl acetate, mix gradient solvent and carry out gradient elution, TLC detects wash-out process, collect sherwood oil, the volume ratio of ethyl acetate is the elutriant of 5:1, remove the solvent in this elutriant, obtain solids, and repeatedly with sherwood oil ethyl acetate, mix gradient solvent and carry out gradient elution, finally obtain sherwood oil, the volume ratio of ethyl acetate is the elutriant of 5:1, except desolventizing can obtain Physalin B crystal,
Wherein, carry out in the sherwood oil ethyl acetate mixed solvent of gradient elution, the volume ratio of sherwood oil, ethyl acetate is respectively: 100:0; 100:1; 80:1; 50:1; 25:1; 10:1; 5:1; 3:1; 2:1; 1:1.
In step 1), solvent is the ethanol of 85-90vol%, and soaking the multiplicity of extracting is 3 times, and each soak time is 7-10 days, described method of removing solvent in soak solution and moisture is for utilizing Rotary Evaporators decompression recycling ethanol, then moisture is removed in evaporation.
Step 2), in, in each dissolution process, the consumption of sherwood oil was not for having medicinal extract.
In step 3), in each dissolution process, the consumption of ethyl acetate was not for having medicinal extract.
In step 4), the quality of solid substance and ethyl acetate volume ratio are 1g:4-5ml.
In step 4), solid substance is 1:(1-1.5 with the mass ratio of the column chromatography silica gel adding in the solution that contains solid substance).
The application of described Physalin B crystal in preparing anti-inflammation drugs.
Physalin B crystal of the present invention can be made medicine with the acceptable auxiliary material combination of pharmacy.
Pharmaceutically acceptable auxiliary material is at least one in carboxymethyl cellulose, ethyl cellulose, Vltra tears, acrylic resin, cross-linked polyvinylpyrrolidone, sodium starch glycolate, N.F,USP MANNITOL, hexadecanol, stearyl alcohol, talcum powder, Magnesium Stearate, micropowder silica gel.
Below in conjunction with specific embodiment, the present invention is described further:
embodiment 1: the extraction preparation of Physalin B crystal
1, extract
First Ku Zhi 8kg is weeded a garden, the foreign material such as clod, by the stem chopping of plant, leaf, fruit dried need slightly beat and can pulverize, the vegetable material crushing is soaked and is extracted with the medical alcohol of 85vol% concentration, alcohol liquid level did not have vegetable material, to prevent that air from contacting with vegetable material, place a week, extracting solution is dark green solution, pours out extracting solution.Extract for the second time as stated above, extract for the third time.
Extracting solution is merged, with Rotary Evaporators reclaim under reduced pressure alcohol, be concentrated into small volume, by concentrated solution, to furnace pot, furnace pot is placed in water-bath, is concentrated into dryly, obtains extract medicinal extract.
2, refining
By extract medicinal extract (1067g), with grinding, pulverize, then all pour wide-mouth Erlenmeyer flask into, first pour sherwood oil (60-90) into wide-mouth Erlenmeyer flask and do not have medicinal extract, jolting makes sherwood oil fully dissolve soluble part in medicinal extract, standing several minutes, after the clarification of upper strata liquid, pour out petroleum ether dissolution liquid and be filtered in another Erlenmeyer flask, repetitive operation 5-6 time, until petroleum ether dissolution liquid color does not shoal, merge petroleum ether dissolution liquid, concentrate to obtain sherwood oil part (101g).Medicinal extract after Petroleum ether extraction (is the part that is suitable for petroleum ether dissolution in medicinal extract by after Petroleum ether extraction and remaining medicinal extract, i.e. medicinal extract after Petroleum ether extraction), with ethyl acetate solvent, fully dissolve wherein the part that (in the medicinal extract after Petroleum ether extraction) is suitable for acetic acid ethyl dissolution again, standing several minutes, after the clarification of upper strata liquid, pouring out acetic acid ethyl dissolution liquid is filtered in another Erlenmeyer flask, repetitive operation 5-6 time, until acetic acid ethyl dissolution liquid color does not shoal, combined ethyl acetate lysate, concentrated remove ethyl acetate and obtain solid substance (48g).
3, ethyl acetate part is separated
By solid substance (the heavy 48g of sample), use 200ml acetic acid ethyl dissolution, with dropper, suck in pear shape bottle, take 300-400 order column chromatography silica gel 48g and also pour in pear shape bottle, in Rotary Evaporators, mix sample.Until ethyl acetate distilled-to-dryness is mixed sample and is partly put into moisture eliminator dried overnight.With 300-400 order column chromatography silica gel, fill after middle pressure preparative column, by ethyl acetate part loading, use sherwood oil wash-out, flow velocity 50ml/min, system pressure is set as 20.0bar, with every 50ml, collect a elutriant, with concentrated each part of elutriant of Rotary Evaporators, elutriant is carried out to silica gel thin-layer chromatography.As immaculate under visible ray shows, thin layer chromatography board can be put into iodine cylinder to observe spot under the smoked colour developing of iodine vapor or ultraviolet lamp, merge the consistent part of component.Silica gel thin-layer chromatography detects, in sherwood oil elutriant, no sample wash-out is out time, adopt sherwood oil: ethyl acetate=100:1(volume ratio) ratio strengthens the polarity of elutriant, continue wash-out, with thin-layer chromatography method, detect, and adjust sherwood oil: the ratio of eluent ethyl acetate liquid, improve gradually the ratio of ethyl acetate, strengthen the polarity (80:1 of elutriant, 50:1, 25:1, 10:1, 5:1, 3:1, 2:1, 1:1), chemical composition is eluted gradually by polarity is ascending, obtain 10 flow point (F1-F10, F1 flow point is sherwood oil: ethyl acetate=100:0, F2 flow point is sherwood oil: ethyl acetate=100:1, F3 flow point is sherwood oil: ethyl acetate=80:1, by that analogy), wherein F7 flow point is except obtaining solids after desolventizing, again with sherwood oil: ethyl acetate gradient solvent carries out gradient elution repeatedly, finally obtain sherwood oil, the volume ratio of ethyl acetate is the elutriant of 5:1, fling to partial solvent and can separate out Physalin B crystal, filtration can obtain Physalin B crystal.
anti-inflammatory activity checking example: monomeric compound anti-inflammatory activity research
1, material and animal
1.1 experiment materials, trial-product and reference substance
2.1 trial-products: the self-control of Physalin B crystal, the front solution that is made into finite concentration (1mg/ml) with physiological saline of experiment;
Positive reference substance: Indometacin Enteric-coated Tablets (GuangDong HuaNan Pharmacy Group Co., Ltd, lot number: 110601), be made into the solution of finite concentration (1mg/ml) before experiment with physiological saline; Negative control product: physiological saline.
2.2 reagent and instrument: dimethylbenzene, lot number 030803-2, Guangzhou Chemical Reagent Factory; Ф 8mm punch tool, electronic balance (FX-300GD, Japanese AND), microscale sampler, tweezers.
1.2 laboratory animal
Germline: 100 of Kunming mouses.
The weight of animals and sex: male, 18～22g.
Animal grade and source:: SPF level mouse, provides (animal production licence number: SCXK(Guangdong) 2008-0002, certification of fitness numbering: 0094517), and supply feed by Guangdong Medical Lab Animal Center.
Raising condition: SPF level Animal Lab., laboratory animal occupancy permit number: SYXK(Guangdong) 2008-0011,23～25 ℃ of room temperatures, relative humidity 40～70%, feeds in feeding standard cage, keeps clean dry in cage.The filling vinyon bottle of purified water, freely drinks for animal, changes water every day once.
Quarantine process: Animal Quarantine phase at least one week of newly buying, at quarantine, observe drinking water for animals, ingest and healthy state, confirm that animal health is anosis, can use.
Drinking-water: the filling vinyon bottle of purified water, for animal, freely drink, change water every day once.
2, experimental technique
SPF level Kunming mouse through quarantining 3 days, selects the mouse that left and right ear is complete, thickness is consistent to be divided at random negative control group, positive controls (concentration 1mg/ml), 10 every group.Gastric infusion 0.2ml/10g, administration is in advance after 60 minutes, and every mouse right ear two sides is coated with dimethylbenzene 0.02ml, and left side auricular concha does not splash into any medicine in contrast.After 30 minutes, draw neck to put to death each group mouse.Along ear baseline, cut ears, with Ф 8mm punch tool, in ears same area, lay circular auricle respectively, with scales/electronic balance weighing, every mouse auris dextra sheet weight deducts left auricle weight difference (mg) and is swelling, the swelling degree of control group and administration group is carried out to statistical procedures with SPSS18, relatively each group difference.
3, experimental result
The results are shown in Table 1.As can be seen here, Physalin B group obviously alleviates the degree (P<0.05 or P<0.01) of mice caused by dimethylbenzene xylene ear swelling.
Table 1 Physalin B p-Xylol causes the restraining effect of mice ear
T check: compare * P<0.05 * * P<0.01 with control group
Above-mentioned test-results shows, under this test conditions, physalin group p-Xylol causes mice ear and has extremely significant restraining effect.
crystal test case: the X-single crystal diffraction result of Physalin B
Fig. 1 is molecular structure and the atom mark of the present invention's Physalin B crystal of extracting preparation; Table 1 is crystalline structure data and the parameter of Physalin B, and this crystal belongs to oblique system, and spacer is P2 (1), unit cell parameters
a=12.4996 (2),
b=14.35620 (10),
c=14.75190 (10),
β=99.8740 (10) °, unit cell volume: 2607.97 (5) 3, crystalline density: 1.382 mg/m3,
z=4,
f(000)=1152, final discrepancy factor
r 1 =0.0407,
wR 2 =0.1056, intermolecular dependence hydrogen bond forms crystalline structure and piles up.
table 1: crystalline structure data and the parameter of Physalin B
Claims (7)
1. Physalin B crystal, is characterized in that: this crystal belongs to oblique system, and spacer is P2 (1), unit cell parameters
a=12.4996 (2),
b=14.35620 (10),
c=14.75190 (10),
β=99.8740 (10) °, unit cell volume: 2607.97 (5)
3, crystalline density: 1.382 mg/m3,
z=4,
f(000)=1152, final discrepancy factor
r 1 =0.0407,
wR 2 =0.1056.
2. the extracting method of Physalin B crystal claimed in claim 1, is characterized in that: comprise the following steps:
1) pulverizes the stem of Ku Zhi, leaf, fruit, and soaked in solvent extracts, and obtains soak solution, removes solvent and moisture in soak solution, obtains medicinal extract;
2) pulverize medicinal extract, with petroleum ether solvent, fully dissolve the soluble part in medicinal extract, sufficient standing, filters; Redissolve, sufficient standing, filters this process for several times, until be suitable in medicinal extract all being gone out by Petroleum ether extraction by the part of petroleum ether dissolution;
3) medicinal extract of upper step being processed through sherwood oil is dried, more fully dissolves the soluble part in medicinal extract by ethyl acetate, and sufficient standing filters; Redissolve, sufficient standing, filters this process for several times, merging filtrate, then remove the ethyl acetate in filtrate, obtain solid substance;
4) solid substance upper step being obtained obtains the solution that contains solid substance with acetic acid ethyl dissolution, in the solution that contains solid substance, add column chromatography silica gel to mix sample again, after ethyl acetate is evaporated completely, silicagel column in dry method, by sherwood oil ethyl acetate, mix gradient solvent and carry out gradient elution, TLC detects wash-out process, collect sherwood oil, the volume ratio of ethyl acetate is the elutriant of 5:1, remove the solvent in this elutriant, obtain solids, and repeatedly with sherwood oil ethyl acetate, mix gradient solvent and carry out gradient elution, finally obtain sherwood oil, the volume ratio of ethyl acetate is the elutriant of 5:1, except desolventizing can obtain Physalin B crystal,
Wherein, carry out in the sherwood oil ethyl acetate mixed solvent of gradient elution, the volume ratio of sherwood oil, ethyl acetate is respectively: 100:0; 100:1; 80:1; 50:1; 25:1; 10:1; 5:1; 3:1; 2:1; 1:1.
3. the extracting method of Physalin B crystal according to claim 2, it is characterized in that: in step 1), solvent is the ethanol of 85-90vol%, soaking the multiplicity of extracting is 3 times, each soak time is 7-10 days, described method of removing solvent in soak solution and moisture is for utilizing Rotary Evaporators decompression recycling ethanol, then moisture is removed in evaporation.
4. the extracting method of Physalin B crystal according to claim 2, is characterized in that: step 2) in, in each dissolution process, the consumption of sherwood oil was not for having medicinal extract.
5. the extracting method of Physalin B crystal according to claim 2, is characterized in that: in step 3), in each dissolution process, the consumption of ethyl acetate was not for having medicinal extract.
6. the extracting method of Physalin B crystal according to claim 2, is characterized in that: in step 4), the quality of solid substance and ethyl acetate volume ratio are 1g:4-5ml.
7. the application of Physalin B crystal claimed in claim 1 in preparing anti-inflammation drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754683.5A CN103755719B (en) | 2013-12-31 | 2013-12-31 | Physalin B crystal and extract preparation method and Physalin B crystal in the application prepared in anti-inflammation drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754683.5A CN103755719B (en) | 2013-12-31 | 2013-12-31 | Physalin B crystal and extract preparation method and Physalin B crystal in the application prepared in anti-inflammation drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103755719A true CN103755719A (en) | 2014-04-30 |
| CN103755719B CN103755719B (en) | 2016-06-08 |
Family
ID=50523077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310754683.5A Active CN103755719B (en) | 2013-12-31 | 2013-12-31 | Physalin B crystal and extract preparation method and Physalin B crystal in the application prepared in anti-inflammation drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103755719B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011357A (en) * | 2017-03-31 | 2017-08-04 | 浙江大学 | A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy |
| CN108392484A (en) * | 2018-02-06 | 2018-08-14 | 贵州省食品药品检验所 | Steroidal compounds are preparing the application in preventing or treating the drug of gastric ulcer and its complication |
| CN109776565A (en) * | 2019-01-28 | 2019-05-21 | 浙江省中医药研究院 | A kind of bitter taste chlorins compound and the preparation method and application thereof |
| CN112618539A (en) * | 2021-01-05 | 2021-04-09 | 广东药科大学 | Application of physalin B in preparation of medicine for treating acute lung injury |
| CN114259525A (en) * | 2022-02-14 | 2022-04-01 | 广东安道医疗器械有限公司 | Calyx seu fructus physalis refined product physalin for treating rhinitis and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422467A (en) * | 2007-11-02 | 2009-05-06 | 华东理工大学 | Immunosuppressant containing Withanolide type compound |
| CN102633861A (en) * | 2012-04-23 | 2012-08-15 | 南京泽朗医药科技有限公司 | Preparation method of physalin B |
| CN102836152A (en) * | 2012-09-17 | 2012-12-26 | 苏州大学 | Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis |
-
2013
- 2013-12-31 CN CN201310754683.5A patent/CN103755719B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422467A (en) * | 2007-11-02 | 2009-05-06 | 华东理工大学 | Immunosuppressant containing Withanolide type compound |
| CN102633861A (en) * | 2012-04-23 | 2012-08-15 | 南京泽朗医药科技有限公司 | Preparation method of physalin B |
| CN102836152A (en) * | 2012-09-17 | 2012-12-26 | 苏州大学 | Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis |
Non-Patent Citations (5)
| Title |
|---|
| LEI MA, ET AL.: "Withaphysanolide A, a novel C-27 norwithanolide skeleton, and other cytotoxic compounds from Physalis divericata", 《TETRAHEDRON LETTERS》 * |
| MASAO KAWAI,ET AL.: "Crystal structures of 5a,6a-epoxy and 2,3-dihydro derivatives of physalin B, a 13,14-seco-16,24-cyclosteroid, and their 1H NMR spectral analysis", 《BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN》 * |
| PETER MANGWALA KIMPENDE,ET AL.: "Isolation, pharmacological activity and structure determination of physalin B and 5b,6b-epoxyphysalin B isolated from Congolese Physalis angulata L.", 《ACTA CRYSTALLOGRAPHICA, SECTION C: CRYSTAL STRUCTURE COMMUNICATIONS》 * |
| 李萍，等，: "酸浆苦素B对活性多形核中性粒细胞化学发光及H2O2产生的影响", 《中药学》 * |
| 杨燕军，等，: "苦蘵的化学成分研究", 《中国药学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011357A (en) * | 2017-03-31 | 2017-08-04 | 浙江大学 | A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy |
| CN108392484A (en) * | 2018-02-06 | 2018-08-14 | 贵州省食品药品检验所 | Steroidal compounds are preparing the application in preventing or treating the drug of gastric ulcer and its complication |
| CN109776565A (en) * | 2019-01-28 | 2019-05-21 | 浙江省中医药研究院 | A kind of bitter taste chlorins compound and the preparation method and application thereof |
| CN112618539A (en) * | 2021-01-05 | 2021-04-09 | 广东药科大学 | Application of physalin B in preparation of medicine for treating acute lung injury |
| CN114259525A (en) * | 2022-02-14 | 2022-04-01 | 广东安道医疗器械有限公司 | Calyx seu fructus physalis refined product physalin for treating rhinitis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103755719B (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khwaza et al. | Ursolic acid-based derivatives as potential anti-cancer agents: An update | |
| Hussain et al. | Ursolic acid derivatives for pharmaceutical use: a patent review (2012-2016) | |
| CN103755719B (en) | Physalin B crystal and extract preparation method and Physalin B crystal in the application prepared in anti-inflammation drugs | |
| US10967030B2 (en) | Traditional Chinese medicine composition for treating psoriasis and method for preparing the same | |
| Di Giacomo et al. | Recent advances in the neuroprotective properties of ferulic acid in Alzheimer’s disease: A narrative review | |
| Dong et al. | Targeting the interplay of autophagy and ROS for cancer therapy: An updated overview on phytochemicals | |
| Aati et al. | Phytochemical profiling, in vitro biological activities, and in-silico studies of Ficus vasta Forssk.: An unexplored plant | |
| Qi et al. | Bioactive compounds, therapeutic activities, and applications of Ficus pumila L. | |
| CN105017345B (en) | The method of four kinds of compounds of extraction and the application simultaneously from selfheal | |
| Delgado-Tiburcio et al. | Pharmacokinetics and biological activity of cucurbitacins | |
| Bernatoniene et al. | Phenolic compounds of Rhodiola rosea L. as the potential alternative therapy in the treatment of chronic diseases | |
| He et al. | Maslinic acid: a new compound for the treatment of multiple organ diseases | |
| Wang et al. | Quebrachitol: global status and basic research | |
| Park et al. | A triterpenoid lupeol as an antioxidant and anti-neuroinflammatory agent: impacts on oxidative stress in Alzheimer’s disease | |
| Labbozzetta et al. | Natural inhibitors of P-glycoprotein in acute myeloid leukemia | |
| Zieniuk et al. | Recent Advances in the Application of Cucurbitacins as Anticancer Agents | |
| Mu et al. | Research progress on the mechanism of action of hesperetin in cerebral ischemia: a narrative review | |
| Prieto-Rodríguez et al. | In vitro and in silico study of the α-glucosidase and lipase inhibitory activities of chemical constituents from Piper cumanense (Piperaceae) and synthetic analogs | |
| CN102503803B (en) | Organic acid compound as well as extraction method and application thereof | |
| CN107056869A (en) | A kind of withanolide class compound and extracting method and application | |
| Begum et al. | Halodule pinifolia (Seagrass) attenuated lipopolysaccharide-, carrageenan-, and crystal-induced secretion of pro-inflammatory cytokines: mechanism and chemistry | |
| CN101919903B (en) | Method for preparing rabdosia rubescens diterpene extract | |
| CN105693812A (en) | Echinocystic acid derivative and application thereof in preparation of anti-tumor medicine | |
| Qu et al. | Characterization of antihyperglycemic constituents and their cytotoxicity from the fruits of Rosa davurica Pall. | |
| Mir et al. | Phytochemical profiling, antioxidant, cytotoxic, and anti-inflammatory activities of Plectranthus rugosus extract and fractions: in vitro, in vivo, and in silico approaches |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |